Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469382 | 0.87 | CYP3A4 (0.34) | CYP3A4CYP11B2CYP17A1CYP11B1HSD11B1 | |
| SCHEMBL15467881 | 0.85 | TRPV1 (0.37) | CYP3A4CYP11B2CYP17A1CYP11B1HSD11B1 | |
| SCHEMBL15468024 | 0.77 | MAP3K14 (0.38) | CYP3A4CYP11B2CYP17A1CYP11B1GRIN2B | |
| SCHEMBL2148122 | 0.73 | OPRL1 (0.42) | P2RX7FNTAFNTB | |
| SCHEMBL23364947 | 0.71 | CYP1A2 (0.39) | FNTAFNTB | |
| SCHEMBL15894663 | 0.71 | CYP1A2 (0.39) | FNTAFNTB | |
| SCHEMBL29439781 | 0.70 | MAP3K14 (0.35) | MAP3K14FNTAFNTB | |
| SCHEMBL22715202 | 0.70 | MAP3K14 (0.35) | MAP3K14FNTAFNTB | |
| SCHEMBL26833404 | 0.70 | OPRL1 (0.33) | FNTAFNTB | |
| SCHEMBL25215626 | 0.70 | F2 (0.35) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819677-A4 | 8-PHENYL-5,6,7,8-HYDROQUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080039494-A1 | 8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2008-02-14 | — | — | US | disclosed |
| EP-1819677-A2 | 8-PHENYL-5,6,7,8-HYDROQUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006060346-A2 | 8-PHENYL-5,6,7,8-HYDROQUINOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039494-A1 | 8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists | TACR1, TACR2, HTR5A | CYP3A4 2996/4885CYP11B2 2806/4885CYP17A1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.